Skip to main content
Premium Trial:

Request an Annual Quote

OncoDNA to Provide Patient Stratification Services for European Cancer Study

NEW YORK (GenomeWeb) – OncoDNA announced today that it will help perform patient stratification in a Phase II precision medicine study in head and neck cancer being run by the European Organization for Research and Treatment of Cancer.

The trial is expected to enroll up to 257 patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing after first-line platinum-based chemotherapy. OncoDNA said that it will use next-generation sequencing and immunohistochemistry assays to analyze patient biopsies and identify potential biomarkers and molecular alterations that can be used to stratify trial participants into different treatment cohorts.

Additional terms of the arrangement were not disclosed.

Earlier this year, OncoDNA signed an agreement to investigate the use of its liquid biopsy technology in personalizing treatments for metastatic colon cancer. And in October, the firm said that it would supply tumor molecular profiling analysis for SOLTI's breast cancer screening program.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.